[1] 曹忆嵘,彭利军,欧阳阳阳,等. 乙型肝炎病毒感染患者肝硬化发生相关临床危险因素评价. 肝脏,2013,18:211-215.
[2] 厉有名.酒精性肝病的流行病学特点.实用肝脏病杂志,2012,15:180-182.
[3] 王贵强,王福生,成军,等. 慢性乙型肝炎防治指南(2015年版). 中华实验和临床感染病杂志(电子版),2015,9:570-589.
[4] 中华医学会肝病学分会脂肪肝与酒精肝病学组.酒精性肝病诊疗指南(2010年修订版).中华肝脏病杂志,2010,18:167-170.
[5] Rockey DC. Antifibrotic therapy in chronic liver disease.Clin Gastroenterol Hepatol,2005,3:95-107.
[6] Osakabe K, Ichino N, Nishikawa T,et al.Reduction of liver stiffness by antiviral therapy in chronic hepatitis B.J Gastroenterol,2011,46:1324-1334.
[7] Takemoto R, Nakamuta M, Aoyagi Y, et al. Validity of fibroscan values for predicting hepatic fibrosis stage in patients with charonic HCV infection.J Dig Dis,2009,10:145-148.
[8] Nguyen-Khac E, Saint-Leger P, Tramier B,wt al. Noninvasive diagnosis of large esophageal varices by Fibroscan:strong influence of the cirrhosis etiology.Alcohol Clin Exp Res,2010,34:1146-1153.
[9] Wong GL,Wong VW,Choi PC,et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B petient.Clin Gastroenterol Hepatol,2009,7:227-233.
[10] Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stifness measurement by transient elastography(Fibroscan) for liver fibrosis in chronic hepatitis B.Viral Hepat,2009,16:36-44. |
